Journal
CALCIFIED TISSUE INTERNATIONAL
Volume 106, Issue 5, Pages 476-485Publisher
SPRINGER
DOI: 10.1007/s00223-020-00669-4
Keywords
Osteoporosis; Vitamin K2; Menaquinone-7; Bone mineral density; Postmenopausal women
Categories
Funding
- Applied Technology Research and Development Plan of Heilongjiang Province [GA18C005]
Ask authors/readers for more resources
Previous studies indicated a positive effect of vitamin K2 (VK2) supplementation on bone turnover biomarkers and bone mineral density (BMD), but the doses varied, and few studies have focused on the difference between VK2 supplementation alone and in combination with calcium and vitamin D-3. The aim of this study was to explore a low and effective dose of VK2 for improving BMD, and to examine whether the co-supplementation of VK2, calcium and vitamin D-3 would bring greater effects. In this trial, a total of 311 community-dwelling men and postmenopausal women aged 50 and 75 years were randomly assigned to four groups, receiving placebo, 50 mu g/day, 90 mu g/day or co-supplementation with calcium (500 mg/day) and vitamin D-3 (10 mu g/day) for 1 year. At the endpoint, the bone loss of femoral neck was significantly lower in postmenopausal women in the two 90 mu g groups (treatment x time, p = 0.006) compared with placebo, but no effects in men. Serum biomarkers cOC/ucOC ratio increased in the intervention groups (treatment x time, p < 0.001). VK2 supplementation in dose of 90 mu g/day performed a significant effect on reducing bone loss in postmenopausal women, but in combination with calcium and vitamin D-3 brought no additional effects. Trial registration This trial was registered at as chiCTR1800019240.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available